Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Mateon Therapeutics — Investor Presentation (June 2019)
19 slides from Oncotelic Therapeutics's investor presentation, Jun 4, 2019
Slide 1: Self Immunization Protocol (SIP) Against Cancers: TGF-B RNA Therapeutics
BP 2 ONCOTELIC ee Self Immunization Protocol (SIP©) Against Cancers TGF-B RNA THERAPEUTICS
Slide 2: Forward-looking Statements
ONCOTELIC (TT 4 Forward-looking Statements @ This document contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact
Slide 3: Overview of Oncotelic/MATN Opportunity
ONCOTELIC* Overview of Oncotelic/MATN Opportunity Oncotelic Inc. - a leader in TGF-B cancer immunotherapy “+ Robust Data Navigational Platform for rapid data analytic and visualization Self Immunization Protocol (SIP®) using a TGF-B antisense (OT-101) “+ OT-101 is designed to mobilize, stimulate and
Slide 4: Cancer - Current Landscape
sf ONCOTELIC @ Cancer- Current Landscape @ = In 2015- cancer death increased globally to 8.8 million of the 55.8 million deaths- or 1 of every 6 deaths. @ = In 2035- cancer death and new cases are projected to be 14.6 million and 24 million respectively. AACR Cancer Progress Report 2018 @ Although t
Slide 5: Genetic mutations and mutation-based vaccines
sf ONCOTELIC Genetic mutations are characteristics of cancer and are associated with treatment failures. Harnessing innate immunity against these neoepitopes has potential lasting disease control Mutation-based vaccines are agnostic to the cancer type and universally applicable to any patient. Howev
Slide 6: TGF-B Self Immunization Protocol (SIP) - Oncotelic Invention
ONCOTELIC — TGF-B Self Immunization Protocol (SIP©) - Oncotelic Invention ® 1c F-B inhibitor (i.e. OT-101) lifts the immunosuppression and primes the innate immunity against the tumor. Xenogenization CTL- @ + Proliferation + Exocytosis of Alkylating Agent (Hypermutation) Granules @ Subsequent Treg-
Slide 7: Optimal Sequencing for TGF-B Self Immunization Protocol
ONCOTELIC® | y Optimal Sequencing for TGF-B Self Immunization Protocol Proper Sequencing is key to optimal immunotherapy 2. Expand immune reserve through IL-2 treatment or infusion of immune cells 3. Prime immune response with TGF-f inhibitor- OT-101 ~~ Boost immune response with chemotherapy 5. Rev
Slide 8: TGF-B Is Centrally Important Target in Immunotherapy
ONCOTELIC TGF-B Is Centrally Important Target in Immunotherapy @ The overexpression of transforming growth factor-beta, specifically TGF-82, plays a key role in malignant progression of various tumors by inducing proliferation, metastasis, angiogenesis, and immunosuppression Therefore, reducing TGF-
Slide 9: OT-101: Drug Product - TGF-B2 Antisense
9 | y OT-101: Drug Product- TGF-B2 Antisense. ONCOTELIC® Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-B2 messenger RNA Ready for registration trials--Over 200 patients treated across 6 clinical trials Potential for breakth
Slide 10: OT-101: Clinical Efficacy - TGF-B2 Antisense
OT-101: Clinical Efficacy-TGF-B2 Antisense. + TGF-B platform to mobilize, stimulate and boost immunity + Proven tumor reduction in both treated and against cancer untreated tumors + Placement in front of standard chemotherapy allowing for + Safety demonstrated in >200 pts across more A Tumor Volume
Slide 11: Gliomas: G004 Phase 2b Trial - OT-101 Single Agent Activity
A Tumor Volume ONCOTELIC Gliomas: G004 Phase 2b Trial- OT-101 Single Agent Activity Ptsi#: N = 145, OT-101, N = 89; Control (TMZ/PCV), N = 45 Objective responses were observed among the 87 evaluable patients treated with OT-101: Confirmed Best Objective Responses were: 4 CR (4.7%), 12 PR (12.9%), 31
Slide 12: Pancreatic Cancer: P001 Phase 1/2 Trial
ONCOTELIC* Pancreatic Cancer: P001 Phase 1/2 Trial: OT-101 Single Agent Activity Pts#: 61 (37 with pancreatic cancer; 19 with malignant melanoma; 5 with colorectal cancer) OT-101 was well tolerated. MTD not reached and Efficacy Demonstrated Patient 1006: CR as far out as 77 mos: Surgery: Whipple’s p
Slide 13: CRC/Solid Tumors: IL-2/NK/OT-101
ay CRC/Solid Tumors: IL-2/NK/OT-101 P001- Phase 1/2 Clinical Trial OT-101 treated Patients exhibited variable dynamics in IL-8 levels whereby increases were observed during cycles 1 (days 2, 5), 2 (days 1, 2, 5) and 3 (day 5). R2 squares were 0.8522 and 0.9895 and p values were 0.0011 and 0.0053 for
Slide 14: Melanoma: P001 Phase 1/2 Trial
ONCOTELIC® Melanoma: P001- Phase 1/2 Clinical Trial: OT-101 Single Agent Activity @ = Pts#: 61 (37 with pancreatic cancer; 19 with malignant melanoma; 5 with colorectal cancer) @ = Pts#: 61 (37 with pancreatic cancer; 19 with malignant melanoma; 5 with colorectal cancer) @ OT-101 was well tolerated.
Slide 15: MDS: OT-101
ONCOTELIC® = MDs: OT-101 Acceleron Pharma presented positive phase 3 trial for their TGF-B trap- luspatercept at ASH (Dec 2018). This allows for the acceleration of OT-101 clinical development along the same track and further validate TGF inhibitor as a valid therapeutic agent. @ = The Acceleron’s M
Slide 16: SIP Pipeline Built Around Sequencing
16 <7 ( @ SIP© Pipeline Built Around Sequencing Brain Cancer/ OT-101* + TMZ Pancreatic Cancer/ OT-101* + ABX Melanoma: 01* + CA4P: Nec Solid tumors/ O' Companion Prognostic Testing Discovery Pipeline *Available through Expanded N "icle OT-101 Access Program together with anoparticle 0 idetri yp: Wid
Slide 17: Management Team
ONCOTELIC Vuong Trieu PhD Chief Executive Officer Ororaxis Ge Aicorsso sorrento THERAPEUTICS Fatih Uckun MD Pho MAA, PP CNR CENTER NanSteeRe ogy Chief Medical Officer hints oF MINNBsO18 7 ONantkwest Chulho Park PhD Chief Technology Officer Appted IX Wife icici Erauton Lin, @ayr Pharma Aaicorasor
Slide 18: Board of Directors
18 /—~ |) Board of Directors ONCOTELIC® Vuong Trieu PhD- Chairman Former Executive Chairman/Interim CEO of Marina Biotech (OTCQB:ATRX), Director of Sorrento Therapeutics (Nasdaq:SRNE), Founder, Chairman, CEO of Igdrasol which was acquired by NantPharm. Coaguligand team under Phil Thorpe. Sk EE Nal *
Slide 19: Building The Next Generation Pharma
19 sta ONCOTELIC Mateon/Oncotelic- (OTCQB:MATN)- Building The Next Generation Pharma A ST “es <= —# “1 NAVIGATOR DATA PIPELINE Large Data Analytics Large Clinical Data High Value Pipeline ff Thank You
Mateon Therapeutics — Investor Presentation (June 2019) on 6ix